
Evolving Evidence in the Management of Patients with Non-Small Cell Lung Cancer: Clinical Pearls for the Community Practitioner
This educational activity will feature an expert-led discussion about key clinical data surrounding the use of immune checkpoint inhibitors (ICIs), both as monotherapy and in combination with chemotherapy, to manage patients with advanced non-small cell lung cancer (NSCLC) without actional genomic alterations. In addition to covering data surrounding clinical efficacy of ICIs, expert faculty will also describe immune-related adverse events that must be monitored for and mitigated as they arise.
RELEASED DATE: October 31, 2024
EXPIRATION DATE: October 31, 2025